EGFR and lung cancer: In order to investigate how GYP exerts its anti-LC effects by regulating metabolites and metabolic pathways as well as enhancing the anti-lung cancer effects of chemotherapeutic agents, the relative contents of STAT3, EGFR, MAPK14, and TYMS between the six groups were analyzed by western blot (Figure 11).